Relmada Therapeutics (RLMD) Misses Q3 EPS by 84c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($2.44), $0.84 worse than the analyst estimate of ($1.60).

As of September 30, 2021, the Company had cash and short-term investments of $88.1 million, compared to cash, cash equivalents, and short-term investments of approximately $117.1 million at December 31, 2021.

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance